Final Results Of Avelumab And Axitinib In Rcc In The Javelin Renal 101 Trial

Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial

Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma

Dr. Agarwal on Updated Results of the JAVELIN Renal 101 Trial in Advanced RCC

JAVELIN Renal 101: combination approach for advanced RCC patients | Laurence Albiges

Medicine Matters oncology

JAVELIN Renal 101: avelumab plus axitinib improve PFS for advanced renal cell cancer

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

Results from CABOSUN, METEOR and JAVELIN

Dr. Choueiri on the Impact of the JAVELIN Renal 101 Findings in RCC

Javelin Renal 101 Updated Results

JournalClubJunkie

Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal 101 Trial in RCC

Expert comment on the JAVELIN Renal 101 trial | Markus Joerger

Medicine Matters oncology

Study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma

Combining avelumab and axitinib in advanced renal cell carcinoma (RCC)

Avelumab and axitinib for the treatment of advanced RCC

Promising results for axitinib and pembrolizumab in advanced renal cell cancer

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC

Avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients

infocusrx today

Avelumab plus axitinib shows good efficacy for OS and PFS in aRCC patients

Renal cell carcinoma trial analysis: current landscape of immunotherapy combinations